Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Coric

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
The Journal of Headache and Pain|August 8, 2022
Measuring interictal burden among people affected by migraine: a descriptive survey studyLena T Hubig, Timothy Smith, Emma Williams, et al.
Lancet (London, England)|December 18, 2020
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trialRobert Croop, Richard B Lipton, David Kudrow, et al.
Headache|September 1, 2022
A stated preference survey to explore patient preferences for novel preventive migraine treatmentsLena T Hubig, Timothy Smith, Gin Nie Chua, et al.
Journal of Neurochemistry|August 30, 2024
Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg-AD miceJeremiah Pfitzer, Priyanka D Pinky, Savannah Perman, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviorsDavid A Sasso, Paul S A Kalanithi, Kevin V Trueblood, et al.
Clinical Pharmacology in Drug Development|March 19, 2022
P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy SubjectsRajinder Bhardwaj, Julie L Collins, Joseph Stringfellow, et al.
Biological Psychiatry|November 18, 2005
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smokingGraeme F Mason, Ismene L Petrakis, Robin A de Graaf, et al.
Neurology and Therapy|May 30, 2024
Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc AnalysisGilbert J L'Italien, Evangelos K Oikonomou, Rohan Khera, et al.
The Journal of Headache and Pain|June 8, 2022
Real-World experience of interictal burden and treatment in migraine: a qualitative interview studySiu Hing Lo, Katy Gallop, Timothy Smith, et al.
The New England Journal of Medicine|July 11, 2019
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for MigraineRichard B Lipton, Robert Croop, Elyse G Stock, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
The Journal of Headache and Pain|August 8, 2022
Measuring interictal burden among people affected by migraine: a descriptive survey studyLena T Hubig, Timothy Smith, Emma Williams, et al.
Lancet (London, England)|December 18, 2020
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trialRobert Croop, Richard B Lipton, David Kudrow, et al.
Headache|September 1, 2022
A stated preference survey to explore patient preferences for novel preventive migraine treatmentsLena T Hubig, Timothy Smith, Gin Nie Chua, et al.
Journal of Neurochemistry|August 30, 2024
Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg-AD miceJeremiah Pfitzer, Priyanka D Pinky, Savannah Perman, et al.
Journal of Clinical Psychopharmacology|November 18, 2006
Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviorsDavid A Sasso, Paul S A Kalanithi, Kevin V Trueblood, et al.
Clinical Pharmacology in Drug Development|March 19, 2022
P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy SubjectsRajinder Bhardwaj, Julie L Collins, Joseph Stringfellow, et al.
Biological Psychiatry|November 18, 2005
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smokingGraeme F Mason, Ismene L Petrakis, Robin A de Graaf, et al.
Neurology and Therapy|May 30, 2024
Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc AnalysisGilbert J L'Italien, Evangelos K Oikonomou, Rohan Khera, et al.
The Journal of Headache and Pain|June 8, 2022
Real-World experience of interictal burden and treatment in migraine: a qualitative interview studySiu Hing Lo, Katy Gallop, Timothy Smith, et al.
The New England Journal of Medicine|July 11, 2019
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for MigraineRichard B Lipton, Robert Croop, Elyse G Stock, et al.
Pageof 9